Medication Review: Anti-Drug Antibody Development With Guselkumab in Psoriasis, PsA & IBD

In this Medication Review, Lisa Asfahani, PA-C, discusses anti-drug antibody development and immunogenicity associated with guselkumab in the treatment of psoriatic arthritis. The video reviews the IL-23 p19 mechanism of action, how neutralizing antibodies can impact drug efficacy and safety, and what current research shows about antibody rates in guselkumab-treated patients. Key studies, available assays for therapeutic drug monitoring, and practical clinical considerations are highlighted to help rheumatology providers optimize long-term treatment outcomes.